Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFWD.L Regulatory News (FFWD)

  • There is currently no data for FFWD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investee Company Update: Intensity Therapeutics

26 Jun 2019 08:56

RNS Number : 4715D
FastForward Innovations Limited
26 June 2019
 

26 June 2019

 FastForward Innovations Limited

("FastForward" or the "Company")

Investee Company Update: Intensity Therapeutics Inc.

The Board of AIM-traded FastForward Innovations Limited, trading under the symbol FFWD, ("FastForward", the "Company" or "FFWD"), notes the following announcement released on 25 June 2019 concerning investee company Intensity Therapeutics  Inc. ("Intensity"). FastForward has a current equity interest totalling 1.99% in the stock of Intensity.

The announcement is set out below without material changes or adjustments.

Intensity Therapeutics Announces Clinical Collaboration with Merck

· Phase 1/2 clinical trial to evaluate Intensity's INT230-6 in combination with KEYTRUDA® (pembrolizumab) for multiple solid tumor types

Westport, Conn. - June 25, 2019 Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced that it has entered into an agreement with Merck (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of Intensity's lead product candidate INT230-6 and KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy, in patients with advanced solid malignancies including pancreatic, bile duct, squamous cell and non-MSI high colon cancers.

"Our research suggests our product, INT230-6, which enables improved recognition of cancer by the immune system, may exhibit additional effect when combined with anti-PD-1 antibodies," said Lewis H. Bender, President and Chief Executive Officer of Intensity Therapeutics. "We are excited to be working with Merck, one of the world's leading cancer immuno-oncology companies, on our current Phase 1/2 clinical trial to explore the combination of INT230-6 and KEYTRUDA® in cancers with high unmet medical need. We are looking forward to initiating the combination portion of our program in the second half of this year."

Ian. B. Walters, M.D., Intensity's Chief Medical Officer, added, "We will be able to test the combination in a variety of difficult to treat tumors that historically have been non-responsive to checkpoint inhibitors. INT230-6 has demonstrated monotherapy activity, as well as a favorable safety profile, in patients with advanced cancers."

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.

 

About INT230-6

INT230-6, Intensity's lead product candidate designed for direct intratumoral injection, is comprised of two proven, potent anti-cancer agents and a penetration enhancer molecule that helps disperse the drugs throughout tumors and diffuse into cancer cells. INT230-6 is being evaluated in a Phase 1/2 clinical study (NCT03058289) in patients with various advanced solid tumors. In preclinical studies, INT230-6 eradicated tumors by a combination of direct tumor kill and recruitment of dendritic cells to the tumor micro-environment that induced anti-cancer T-cell activation. Treatment with INT230-6 in in vivo models of severe cancer resulted in substantial improvement in overall survival compared to standard therapies. Further, INT230-6 provided complete responder animals with long-term, durable protection from multiple re-inoculations of the initial cancer and resistance to other cancers. In mouse models, INT230-6 has shown strong synergy with checkpoint blockage, including anti-PD-1 and anti-CTLA4 antibodies. INT230-6 was discovered from Intensity's DfuseRxSM platform.

About Intensity Therapeutics

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases. INT230-6, Intensity's lead product candidate, is being evaluated in a Phase 1/2 clinical study in patients with various advanced solid tumors. For more information, please visit www.intensitytherapeutics.com and follow us on Twitter @IntensityInc.

 

FastForward Innovations Limited

info@fstfwd.co

Guerhardt Lamprecht / Lance De Jersey / Ed McDermott

Beaumont Cornish Limited (Nomad) Tel: +44 (0) 207 628 3396

James Biddle / Roland Cornish

 

 

Optiva Securities Limited (Broker) Tel: +44 (0) 203 411 1881

Jeremy King/ Graeme Dickson

For further information please visit www.fstfwd.co or contact:

CAUTIONARY STATEMENT

The AIM Market of London Stock Exchange plc does not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of Fast Forward Innovations Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognizable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Fast Forward Innovations assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDGRGDLGUDBGCL
Date   Source Headline
12th Jul 20216:15 pmRNSUpdate on timetable for Change of Name
9th Jul 20214:00 pmRNSResult of EGM and Change of Name
7th Jul 20217:00 amRNSFurther Investment in South West Brands Limited
6th Jul 20217:00 amRNSInvestment in cannabis healthcare company- CiiTECH
5th Jul 20217:00 amRNSNew investment - European medical cannabis company
28th Jun 20217:30 amRNSSale of Shares in Portage Biotech
28th Jun 20217:00 amRNSFurther Investment in Little Green Pharma Ltd
22nd Jun 20213:30 pmRNSNotice of EGM & Proposed Change of Name
22nd Jun 20213:00 pmRNSInvestee Company Update: Little Green Pharma Ltd
10th Jun 20217:00 amRNSPurchase of further shares in Little Green Pharma
1st Jun 20217:00 amRNSInvestee Company Update: Yooma Wellness Inc.
28th May 20217:00 amRNSInvestee Company Update: Little Green Pharma
29th Apr 20217:00 amRNSInvestee Company Update: Yooma Wellness
12th Apr 20219:00 amRNSSpecialist Appointed to Strengthen Team
7th Apr 20214:25 pmRNSCompletion of Sale of Investment in EMMAC
1st Apr 20217:00 amRNSNew Investment in Cannabis Cultivator Company
22nd Mar 20213:26 pmRNSInvestee Company Update: Yooma Wellness
18th Mar 20211:55 pmRNSInvestee Company Update: Yooma Wellness Inc.
15th Mar 20217:00 amRNSInvestee Company Update: Leap Gaming
11th Mar 20218:00 amRNSSale of Investments in Kanabo and Cellular Goods
10th Mar 20217:00 amRNSConditional Sale of Investment in EMMAC
8th Mar 202110:21 amRNSInvestee Update: Portage Biotech & Juvenescence
3rd Mar 20217:00 amRNSNew Corporate Presentation
2nd Mar 20212:06 pmRNSInvestee Update: EMMAC Life Sciences and Yooma
1st Mar 20217:00 amRNSNew Investment in Consumer Cannabinoid Company
26th Feb 20214:30 pmRNSHolding(s) in Company
26th Feb 20214:30 pmRNSHolding(s) in Company
26th Feb 20217:15 amRNSInvestor Presentation
26th Feb 20217:00 amRNSCorporate Update
23rd Feb 20214:40 pmRNSSecond Price Monitoring Extn
23rd Feb 20214:35 pmRNSPrice Monitoring Extension
22nd Feb 20218:15 amRNSHolding(s) in Company
18th Feb 20212:05 pmRNSSecond Price Monitoring Extn
18th Feb 20212:00 pmRNSPrice Monitoring Extension
18th Feb 20219:37 amRNSInvestee Company Update: Little Green Pharma Ltd
16th Feb 20212:00 pmRNSPrice Monitoring Extension
16th Feb 202112:20 pmRNSInvestment in Medical Cannabis Company
12th Feb 20217:00 amRNSNew Investment in Medical Cannabis Business
11th Feb 20213:44 pmRNSInvestee Company Update: Portage Biotech Inc.
11th Feb 202110:33 amRNSInvestee Company Update: Yooma Corp.
2nd Feb 202111:09 amRNSInvestee Company Update: Leap Gaming
1st Feb 20217:00 amRNSInvestment - CBD Brand Business, South West Brands
29th Jan 202110:40 amRNSPlacing to raise £2.1 million
26th Jan 20214:12 pmRNSInvestee Company Update: EMMAC Life Sciences
26th Jan 20212:14 pmRNSInvestee Company Update: Yooma Corp.
20th Jan 202112:00 pmRNSInvestee Update: EMMAC Life Sciences & Yooma Corp.
16th Dec 20207:00 amRNSFurther Investment in EMMAC Life Sciences Group
10th Dec 20207:00 amRNSInterim Results
30th Nov 20207:00 amRNSEd McDermott Appointed to the Board of Leap Gaming
24th Nov 20207:00 amRNSInvestee Company Update: Yooma Corp.

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.